BioTiChe today announced the successful achievement of the first milestone under its agreement with Autifony Therapeutics. While details remain confidential, this milestone marks an important step forward in our R&D efforts and highlights the strength of BioTiChe’s integrated chemistry and biology teams, as well as its commitment to scientific excellence.
Dr. Giuseppe Alvaro, Chief Executive Officer of BioTiChe, commented: “In a world where success is often measured primarily by the ability to raise funding around innovative biological ideas, we take a different view. While new ideas are essential, we believe that success is ultimately defined by the ability to translate those ideas into tangible progress by seeing a scientific programme mature and its molecules advance through the discovery process toward becoming medicines for patients.
”In a world where success is often measured primarily by the ability to raise funding… we believe that success is ultimately defined by the ability to translate those ideas into tangible progress”
– DR. GIUSEPPE ALVARO
Achieving this transformation requires persistence, scientific creativity, and strong collaboration across teams. In my view, this is the true measure of success in drug discovery, and it is what BioTiChe represents.”
He added:
“I look forward to seeing further milestones achieved by the BioTiChe team”.
This achievement reflects the dedication, expertise, and collaborative spirit of the BioTiChe team, which remains central to the company’s continued progress.
